Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3073763 | 0.83 | NAMPT (0.45) | MEN1HSP90AA1KMT2ANAMPTCYP3A4 | |
| SCHEMBL5557508 | 0.77 | NAMPT (0.47) | C3AR1NAMPTCYP3A4CYP2C9 | |
| SCHEMBL3079575 | 0.77 | NAMPT (0.45) | MEN1HSP90AA1KMT2AC3AR1NAMPT | |
| SCHEMBL81910 | 0.77 | PTAFR (0.50) | MEN1KMT2AC3AR1NAMPTCYP3A4 | |
| SCHEMBL82430 | 0.76 | PTAFR (0.49) | MEN1KMT2AC3AR1NAMPTCYP3A4 | |
| SCHEMBL81394 | 0.76 | PTAFR (0.49) | MEN1KMT2AC3AR1NAMPTCYP3A4 | |
| SCHEMBL3080363 | 0.76 | NAMPT (0.45) | MEN1HSP90AA1KMT2AC3AR1NAMPT | |
| SCHEMBL82722 | 0.75 | PTAFR (0.56) | C3AR1NAMPTCYP3A4CYP2C9 | |
| SCHEMBL3079286 | 0.75 | PTAFR (0.48) | C3AR1NAMPTCYP3A4CYP2C9 | |
| SCHEMBL83930 | 0.74 | LMNA (0.49) | MEN1KMT2AC3AR1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | KLINGE PHARMA GMBH | 2004-09-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | ALK, ANXA1, ANXA11 | MEN1 1876/4885HSP90AA1 2379/4885KMT2A 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.